The GABA A R is a preeminent member of the pentameric ligandgated ion channel (pLGIC) superfamily comprising, amongst others, the nicotinic acetylcholine (nAChR), glycine (GlyR) and serotonin type 3 (5-HT 3 R) receptors 1,2 . GABA A Rs possess an anion-selective ion channel that, following agonist activation, enables Cl − flux to shunt and often hyperpolarize the membrane, thus revealing their primary task in the brain, which is to inhibit neuronal excitation 3 . It is widely acknowledged that dysfunctional GABA signaling results in neurological disorders 4, 5 .
The GABA A R is a preeminent member of the pentameric ligandgated ion channel (pLGIC) superfamily comprising, amongst others, the nicotinic acetylcholine (nAChR), glycine (GlyR) and serotonin type 3 (5-HT 3 R) receptors 1, 2 . GABA A Rs possess an anion-selective ion channel that, following agonist activation, enables Cl − flux to shunt and often hyperpolarize the membrane, thus revealing their primary task in the brain, which is to inhibit neuronal excitation 3 . It is widely acknowledged that dysfunctional GABA signaling results in neurological disorders 4, 5 .
GABA signaling via type A receptors occurs through a combination of rapid phasic and persistent tonic inhibition. The former requires the activation of synaptic GABA A Rs composed of αβγ subunits clustered at inhibitory synapses. The latter involves diffusely located extrasynaptic GABA A Rs comprising αβγ and αβδ subunits 3, 6 . Although varying the receptor subunit composition confers distinctive physiological and pharmacological properties 7 , all GABA A Rs share core fundamental properties. Both synaptic and extrasynaptic receptor classes desensitize [8] [9] [10] upon prolonged agonist exposure, and both are modulated by naturally occurring brain neurosteroids 11 that 'fine-tune' the time course and extent of postsynaptic inhibition.
An important and common structural denominator for most GABA A Rs is the α subunit. There are six isoforms (α1-α6), among which α1 is the most widely expressed in the brain 12 . In combination, α1 with β2/3 and γ2 subunits form prototypic synaptic GABA A Rs. The extracellular domain (ECD) of the α subunit is vital in forming part of the interfacial GABA-binding sites between the β and α subunits. Notably, structural elements within the transmembrane domain (TMD) of the α subunit shape GABA channel architecture and strongly influence the biophysical and pharmacological properties of individual GABA A R subtypes 7, 13 , including their modulation by neurosteroids 14 and general anesthetics 15 . Naturally occurring neurosteroids are synthesized in the brain from cholesterol and represent a potent endogenous modulator of GABAergic transmission. These compounds can modulate both synaptic and extrasynaptic receptors 11 and are classified on the basis of their ability to potentiate or inhibit GABA A R activity. Notably, the GABA A R α-subunit TMD confers sensitivity to neurosteroids such as allopregnanolone and its derivatives 14 .
A further understanding of GABA A R function and its dependence on modulation by allosteric ligands requires the generation of new structural information. This information will also provide insight into the disruptive effects of receptor mutations that are associated with neuropsychiatric diseases 16 . To date, structural studies have been limited mainly to a reliance on homology modeling and structural comparisons between homologous pLGIC members for which atomic-level resolution is available 2 .
Here, we describe structural details of the GABA A R at atomic resolution, using a new chimera-based modular construct. We present crystal structures of the GABA A R α1-subunit TMD alone and in complex with the two classes of brain neurosteroids: the potentiating stress hormone-derived tetrahydro-deoxycorticosterone (THDOC) and the inhibitory neurosteroid pregnenolone sulfate (PS). These new receptor structures also allow clear observation of the GABA ion channel for which we can resolve the recently defined desensitization gate that lies deep within the pore 10 .
RESULTS

Designing a functional GABA A R chimera
To provide high-resolution X-ray crystallographic structural information for the TMD of GABA A Rs, we developed a new 'prokaryotic-eukaryotic' chimera, which involved fusing the ECD of the a r t i c l e s prokaryotic homolog GLIC from Gloeobacter violaceus 17, 18 with the TMD (comprising the α-helices M1-M4 and associated linkers) from the α1 subunit of GABA A Rs ( Fig. 1a and Supplementary  Fig. 1a ). GLIC was selected for constructing the chimera because it readily crystallizes as a homomer 17, 18 , with principal crystal contacts contributed by the ECD. Moreover, GLIC forms a functional chimera when fused to the TMD of a similar pLGIC, the GlyR 19 . Finally, the kinetic profiles of proton-activated currents for wild-type (WT) GLIC are slow and distinct from those for most GABA A Rs (Fig. 1b) , which enables the functional and pharmacological characteristics of the chimeric GABA A R α1-subunit TMD to be readily identified.
Previous studies of pLGICs have revealed that the interfacial loops at the base of the ECD and the extracellular segments of the TMD are important for transmitting the process of agonist binding to ion channel opening 1 . In the chimera, loops 2, 7 and 9 at the base of the ECD β-sheets, which are important for transmitting the agonist-binding signal 1 , are contributed by GLIC, whereas the M2-M3 linker of the TMD derives from the α1 subunit of GABA A Rs ( Supplementary  Fig. 1a ). To optimize the chimera for crystallization, the large intracellular M3-M4 domain was replaced with the shorter linker from GLIC, -SQPARAA-( Fig. 1a and Supplementary Fig. 1a ).
Functional properties of the GABA A R chimera
To ensure that the GLIC-GABA A Rα1 chimera was functional, the receptors were expressed in Xenopus oocytes and assessed using twoelectrode voltage-clamp (TEVC) electrophysiology. As predicted for a chimera incorporating the ECD from GLIC and the TMD from the GABA A R α1subunit, it was activated by protons in a concentration-dependent manner, yet formed a Cl − -selective ion channel characteristic of GABA A receptors ( Supplementary Fig. 1b-d) . Accordingly, proton-activated currents were inhibited by the GABA channel blocker picrotoxin (Fig. 1c,d) . Furthermore, prolonged proton applications evoked desensitization of Cl − currents, similar to response profiles for α1β3 GABA A Rs activated by high GABA concentrations, and therefore distinct from the slower response of WT GLIC channels (Fig. 1b) . Protons can modulate native GABA A Rs, but this modulation is critically dependent on a histidine residue in the TMD of the β subunit 20 . The equivalent residue is absent in our chimera, thereby suggesting that residues in the ECD determine the sensitivity to protons.
To further validate the chimera as a new model for α1 subunitcontaining GABA A Rs, we mutated key residues within the TMD that underpin gating transitions and affect receptor desensitization ( Supplementary Fig. 1e ). Consistent with results from α1β2 GABA A Rs 10 , mutating valine 251 at −3′ in M2 (numbered from a conserved arginine at the base of M2 defined as position 0′) to isoleucine (V251I) or by mutating glycine 258 (4′) to valine or alanine (G258V/A) yielded chimeras exhibiting profound desensitization following proton activation (Fig. 1e) . Thus, the characteristics of the chimera TMD are in agreement with those expected of the GABA α1-subunit TMD.
Crystal structure of the GABA A R chimera After screening for the expression and purification of various receptor chimeras in Sf9 insect cells, we noted that the purification of GLIC-GABA A Rα1 was markedly improved by including the desensitizing G258V mutation ( Supplementary Fig. 2a,b) . Notably, this receptor (GLIC-GABA A Rα1 G258V cryst ) retained its functionality (Fig. 1b) and was thermostable as a pentamer in detergent micelles ( Supplementary Fig. 2c,d) .
We determined the crystal structure of GLIC-GABA A Rα1 G258V cryst at 2.8-Å resolution under low pH to capture the receptor in an agonist-bound desensitized conformation ( Table 1 and Supplementary  Fig. 3 ). The chimera forms a homopentamer with each subunit composed of an ECD, comprising inner and outer layers of β-sheets from GLIC, coupled to four α-helices in the TMD with an integral pore from the α1 subunit (Fig. 2) . A continuous solvent-accessible pathway (characteristic of all pLGICs) follows a five-fold symmetry axis through the center of the ECD and TMD. A positive electrostatic surface potential extending the length of the TMD is conducive to Cl − permeation ( Supplementary Fig. 4 ). The ECD structure is compact 21, 22 , with bound acetate ions contributed by the crystallization solution, consistent with that of the agonist-bound state for WT GLIC 23, 24 .
The ECD (Supplementary Note 1) is connected to the GABA α1-subunit TMD through extensive interactions between ECD loops 2, 7 and 9 and the M2-M3 linker of the TMD (Fig. 3) . Crucially, by adopting a cis conformation, the conserved proline (P120) at the tip of loop 7 (ref. 23 Figure 1 Structure and function of the GLIC-GABA A Rα1 chimera. (a) Schematic representation of the GLIC-GABA A Rα1 chimera. The ECD is contributed by the GLIC subunit (green, residues ) and the TMD is from the GABA A R α1 subunit (blue, residues 223-428) excluding the intracellular domain between M3 and M4, which is derived from GLIC (green loop). (b) Peak-scaled currents induced by applied (bar) orthosteric agonists for: α1β3 GABA A R (10 mM GABA); wild-type (WT) GLIC (protons, pH 4); and chimera constructs with and without the G258V mutation (proton, pH 4). GLIC-GABA A Rα1 G258V cryst was used for crystallization experiments. (c) The GABA A channel blocker picrotoxin (PTX; 1 mM) inhibits proton-activated currents (pH 4) in the chimera voltage-clamped at −60 mV. Dotted lines show the extent of steady-state current inhibition. (d) Bar graph showing current remaining after PTX inhibition of peak and steady-state pH 4 currents. Values are means ± s.e.m. (n = 4 independent experiments). Note the peak currents are more profoundly inhibited by PTX than are steady-state currents. (e) Peak-scaled proton-activated (pH 4-4.5) currents (V H = −60 mV) for chimeras with gain-of-desensitization mutations in the α1-subunit TMD 10 . Increased residue side chain volume at the −3′ valine and 2′ glycine in M2 increases the rate of desensitization. Source data for d are available online. a r t i c l e s also forms a hydrogen bond with the backbone amino group of F115 on loop 7. This interaction further stabilizes domain coupling (Fig. 3b) . The conserved nature of these ECD-TMD interactions ensures that ion-channel gating follows agonist binding. It also highlights the critical role of the highly conserved K278 in the M2-M3 linker 25 ( Fig. 3b,c) , which is also conserved in GLIC (K248). Previous studies of α1β2γ2 GABA A Rs revealed a role for this residue in the initiation of channel gating 26 in which it probably stabilizes an open state of the GABA A R 27 . Furthermore, disruption of these interactions through mutation of residues in α1 subunits causes familial epilepsies 28 .
The geometry of the GABA A R α1-subunit pore (Fig. 4) exhibits structural similarities to those of other pLGICs under nonresting conditions, including GLIC at acidic pH in an 'agonist-bound' state 17, 18 , glutamate-activated Cl − channels (GluCl cryst ) bound to ivermectin 29 , GABA β3 homomers bound with benzamidine 30 , and ligand-bound GlyRα1 (ref. 31) and GlyRα3 (ref. 32) . The channel lining M2 α-helices reveal an expanded pore at the extracellular portal (at 20′; Fig. 4a,b ) that gradually tapers towards the intracellular exit at −2′, which is characteristic of a desensitized conformation (Fig. 4b,c) . This structure is distinct from that of GLIC-GlyRα1, which adopts a locally closed conformation when crystallized at a low pH 19 (Supplementary Fig. 5 ). In addition to M2, both the M1 and M3 α-helices of the GLIC-GABA A Rα1 chimera superimposed onto related pLGIC TMD structures. However, the extracellular end of M4 was rotated around a highly conserved proline (P400), compared to M4 in GABA β3 homomers (Fig. 4a) .
At the extracellular end, the expanded pore is stabilized by an intrasubunit salt bridge between R273 (19′ in M2) and D286 (in M3) and by intersubunit hydrogen bonds between N274 (20′ in M2) and Q228 (in M1, which is also highly conserved across most GABA A R subunits; Fig. 3c) . Notably, although two cysteines on a r t i c l e s M1 (C233) and M3 (C292) are in proximity to one another, they do not form a disulfide bridge (as proposed from homology-modeling studies 33 ). Deeper in the pore, the leucine ring at 9′ that is associated with the activation gate 34 is open (pore radius ~5 Å), with side chains rotated out toward M2 of the adjacent subunit. This rotation is also observed in structures of the GABA receptor β3 homomer, GlyRα1, and GlyRα3 bound to ivermectin 30, 31, 35 ( Fig. 4b and Supplementary Fig. 5 ).
Further into the pore, two constrictions are evident, formed by rings of residues at 2′ (valine) and −2′ (proline; Fig. 4d,e and  Supplementary Fig. 5 ). This region forms the 'desensitization gate' recently described for GABA A Rs and GlyRs 10 and the ion-selectivity filter 23 . The pore is narrowest at the −2′ proline (2.1-Å radius), allowing the passage of Cl − lacking a hydration shell (1.8-Å radius), though precluding hydrated Cl − (~3.3-Å radius; Fig. 4b-d and Supplementary Fig. 5 ). Analyzing the surface potential electrostatics of the channel revealed an electropositive region at the intracellular end ( Fig. 4f and Supplementary Fig. 4 ), which can facilitate anionselective permeation. This potential probably arises from side chain dipoles in M2 α-helices 29 . Given that the chimera channel is anion selective, peaks in electron density maps in the pore were tentatively assigned to Cl − ions (~6 σ in F o − F c maps). This location is in spatial proximity to the anion-binding sites proposed for the anion-selective GluCl 29 and GlyRα3 channels 36 . Moreover, a self-stabilized arrangement of water molecules, similar to those in GLIC 23 , is apparent at the level of the 6′ threonine ( Supplementary Fig. 4) . Interestingly, at the cytosolic face, the chimera TMD exhibits 'pockets' of positive electrostatic potential, reminiscent of those in anion-selective GluCl channels 29 ( Supplementary Fig. 4 ).
Previous patch-clamp studies of GLIC at pH < 4.5 have revealed that entry into a desensitized state occurs within ~1.5-10 s 37, 38 . Here, introducing G258V near the physically constricted desensitization gate between 2′ and −2′ of GLIC-GABA A Rα1 resulted in currents that rapidly declined (Fig. 1b,e) , thus suggesting that GLIC-GABA A Rα1 G258V cryst adopts a desensitized conformation at pH 4.5. Indeed, residues known to affect GABA A R desensitization 10 similarly affected proton-activated responses for the chimera (Fig. 1e) and formed steric interactions at the interface between M2 and M3, near the base of the TMD (Fig. 4e) . Our structure reveals that this putative desensitized state is stabilized by intrasubunit salt bridges between R254 (0′ in M2), E302 (M3) and D392 (M4) at the base of the helical bundle and by intersubunit hydrogen bonds between N307 (M3) and the backbone amino group of N247 (in the M1-M2 loop; Fig. 3d ). This finding provides structural evidence for a pLGIC in a desensitized state.
Cholesterol binding to the GABA A R chimera
A common structural feature of the proton-bound chimera was the electron density (~5 σ in F o −F c maps) at a cavity between M3 in the principal (p, +) subunit and M1 from the complementary (c, −) subunit ( Supplementary Fig. 6a,b) . This density was assigned to cholesteryl hemisuccinate (CHS), which was used during purification. The site partially overlaps with sites for lipids and ivermectin in GluCl 29, 39 and for ivermectin in GlyRs 31, 35 ( Supplementary Fig. 6 ). Modeling and refinement of CHS indicated that its orientation best fit the electron density when cholesterol was tilted away from the receptor with the hemisuccinate moiety protruding between M3 and M1. This group could hydrogen-bond with S269 (15′ in M2), which is a key determinant for allosteric modulation of GABA A Rs by volatile anesthetics and of GLIC by ethanol 22, 40, 41 (Supplementary Fig. 6 ). This location for CHS is analogous to that proposed for cholesterol at GABA A Rs from homology modeling and molecular dynamic (MD) simulations 33 . This finding suggests that without the bulky hemisuccinate group, cholesterol can penetrate deeper into this interface, forming a hydrogen bond between the hydroxyl group of the cyclohexanol ring and 15′ serine 33 .
Location of the potentiating neurosteroid-binding site GABA A Rs are major targets in the brain for naturally occurring neurosteroids derived from stress (such as THDOC, Fig. 5a ) or sex hormones 11 (such as allopregnanolone). These molecules potentiate GABA A R function at physiologically relevant nanomolar concentrations, whereas at higher (micromolar) concentrations, they cause direct receptor activation. Given their high potency at GABA A Rs, the potential for therapeutic application of neurosteroids is particularly appealing 42 . A highly conserved binding site underlying the neurosteroid-potentiating action is considered, from homology modeling and mutagenesis studies, to be located within the α-helices of GABA A R α subunits 14 .
To identify the neurosteroid-binding site, we used the GLIC-GABA A Rα1 G258V cryst chimera, which is sensitive to THDOC, as evident from the markedly potentiated proton-activated currents using TEVC and increased thermal stabilization of the detergent-solubilized receptor (Fig. 5b,c and Supplementary Fig. 2e ). Moreover, as for native GABA A Rs, THDOC can also directly activate the chimera in the absence of protons. These effects of THDOC are comparable to those observed with native GABA A Rs (α1β3 EC 50 s for potentiation and direct activation: 0.57 ± 0.1 µM; 2.46 ± 0.02 µM (n = 4 and 3 independent experiments), respectively; Fig. 5c ). We observed no sensitivity to 1-3 µM THDOC for GABA β3 homomers a r t i c l e s (EC 10 pentobarbitone-gated current 99.3 ± 2.0% of control, n = 3) or WT GLIC receptors (EC 20 proton-activated current 93.9 ± 1.7%, n = 7). To explore the basis for neurosteroid binding to GABA A Rs, we determined the structure of GLIC-GABA A Rα1 G258V cryst bound to THDOC at 3.8 Å following co-crystallization. Neurosteroid molecules were bound to the TMD of each subunit. These molecules were not located within the α-helices of the α1 subunit, as previously proposed 14 , but were unambiguously located across the subunit-subunit interface ( Fig. 5d and Supplementary Fig. 7a,b) . The electron density maps allowed confident positioning of the β face of the neurosteroid backbone and orientation of the critical A-ring hydroxyl group at position C3.
At this new site, the ring core of THDOC binds in a 'hydrophobic groove' that runs between juxtaposed subunits, anchored by hydrogen bonds at each end of the molecule. This structure conforms to that of a canonical steroid-binding site (Fig. 5e,f and Supplementary Fig. 7) . The architecture of this site and the strong electron density for bound THDOC confirmed the pivotal binding role previously assigned to Q241 in M1 of the α1 subunit 14 . A single hydrogen bond is formed between Q241 in the complementary subunit and the C3α hydroxyl in ring A of THDOC (Fig. 5e,f) . The importance of Q241 was demonstrated through the mutation Q241L, which ablated neurosteroid sensitivity ( Fig. 5g) without affecting the proton sensitivity of the chimera (Supplementary Fig. 1d ). The complementary subunit also contributes a tryptophan (W245) to the neurosteroid-binding site, which is critical for neurosteroid potentiation at recombinant GABA A Rs 43 . The indole side chain of W245 is oriented parallel to THDOC rings C and D, presumably interacting via hydrophobic stacking (Fig. 5e,f) . As predicted, mutation of this residue (W245L) ablated neurosteroid potentiation (Fig. 5g) . The orientation of the neurosteroid is supported by serial mutations of Q241 revealing that potentiation is maintained if the substituent is a hydrogen bond acceptor (like Q, N and H) but not if it only engages as a hydrogen bond donor (like W, R and K) 14 . Given that the C20 ketone of THDOC can only act as a hydrogen bond acceptor, its molecular orientation in the binding site is probably that whereby the C3α hydroxyl of THDOC forms a hydrogen bond to Q241.
Across the subunit interface, THDOC's ring D ketone forms another hydrogen bond with T305 in M3 of the principal subunit (Fig. 5e,f) , and, consistent with a binding role for this residue, its substitution with tryptophan (T305W) ablated THDOC potentiation (Fig. 5g) . The corresponding residue in the β-α interface of native β3-containing GABA A Rs is F301. Interestingly, this residue is photolabeled by a neurosteroid analogue in GABA β3 homomers, in accord with its having a binding role 44 a r t i c l e s subunit is formed by the aromatic ring of Y308, a residue that is highly conserved across GABA A R subunits. In the physiological context of binding at the β-α interface of GABA A Rs, it is apparent that the steroid molecule is also physically supported by aromatic residues contributed by both subunits. Although there is strong conservation of these aromatic residues across inhibitory pLGICs ( Supplementary  Figs. 1e and 7) , modulation by THDOC is primarily dependent on hydrogen bonds at the complimentary face to Q241 in M1. This residue is only provided by the receptors containing the α subunit and is not present in β subunits (Supplementary Fig. 7e ).
We performed MD simulations to corroborate our crystallographic interpretation of the orientation of THDOC in the binding site. Of many potential docking poses, only one consistently mapped onto the crystal structure. In this position, Q241 and W245 coordinate with the A ring of THDOC and T305 coordinates the D ring ( Supplementary Fig. 8a,b and Supplementary Video 1) . The THDOC position remained stable during MD simulation. Notably, the C3α hydroxyl group donated a hydrogen bond to Q241, and the C21 hydroxyl of THDOC was oriented toward the membrane where it could donate a hydrogen bond to the lipid head groups.
Interestingly, the effects of THDOC on receptor structure are subtle. Although such small movements are insufficient to provide extensive insight, it is apparent that the overall structural geometry conforms to that observed for the proton-bound chimera structure in a desensitized state. The THDOC-bound structure thus resembles that of GlyRα1 bound to ivermectin 31 and GlyRα3 bound to the analgesic AM-3607 (ref. 36) , which both potentiate the agonist response. Considering the physical contours and binding interactions of the neurosteroid-binding site described here, and data from previous electrophysiological studies 14 , we would expect this site to a r t i c l e s accommodate potentiating neurosteroids of distinct stereochemistry exhibiting high-efficacy modulation of GABA A Rs 45, 46 .
Inhibitory neurosteroid-binding site involves M3 and M4
GABA A Rs are also modulated by naturally occurring inhibitory neurosteroids in the brain, as exemplified by PS (Fig. 6a) . Their binding site on GABA A Rs has remained elusive, although the consensus view is that PS binds at a discrete site from that for potentiating neurosteroids 47 . Expressing GLIC-GABA A Rα1 G258V cryst in Xenopus oocytes and using TEVC indicated that a PS-binding site was present with an apparent affinity comparable to that for native GABA A Rs (Fig. 6b) . To establish its location, we co-crystallized the chimera with PS (Supplementary Note 2) . Electron density maps for PSbound crystals (at 3.0 Å) revealed distinctive peaks of density along the bilayer-exposed face of M3 and M4 ( Fig. 6c and Supplementary  Fig. 8c) . Modeling of PS suggests that it aligns perpendicularly to the membrane at this intrasubunit site, possibly engaging in van der Waals interactions mainly along the outer face of M4. Although we cannot precisely orient PS at this resolution, MD simulations indicated that the ring A sulfate group points toward the base of the TMD, potentially interacting with K390 (side chain density for which was missing in diffraction data; Fig. 6c, Supplementary Fig. 8c-e and  Supplementary Video 2) . The PS-ring structure most likely interacts with several residues in pM4, including I391, A398 and F399.
PS poses in MD simulations were less stable than those for THDOC, possibly reflecting the labile nature of this site. From different starting orientations, PS had a tendency to transition rapidly into an alternative pose in its proposed binding site. In this position, the β-surface-protruding methyl groups are oriented toward the hydrophobic environment of the membrane, the sulfate group forms a salt bridge with K390, and the PS-ring core interacts with subsequent turns of the M4 α-helix up to L402.
This discrete site and the varied nature of the residues involved may explain the enigmatic nature of PS modulation and account for the difficulties in identifying its binding site 47 . In agreement with the notion of a discrete site, PS inhibition was unaffected by mutating Q241, W245 or T305, which ablated THDOC potentiation ( Fig. 6d  and Supplementary Fig. 8f ) 48 . However, mutating charged (K390A) or hydrophobic (I391C, A398C and F399C) pM4 residues in the chimera significantly reduced the inhibition of steady-state currents by a r t i c l e s PS (Fig. 6e) . To investigate further, we developed a kinetic model (Online Methods) to simulate the effects of PS and the M4 mutations. By assuming that PS binds preferentially to the activated, desensitized states of GLIC--GABA A Rα1 (ref. 47) , the model suggested that the mutations caused small changes (3-4-fold) promoting receptor entry into a desensitized state and increasing entry into agonist-bound blocked states. There was minimal effect on the PS dissociation constant, and overall, the mutated residues had more profound effects on PS efficacy than potency, which may partly explain its mechanism of inhibition ( Supplementary Fig. 8g ).
DISCUSSION
Here we present a new GABA A R chimera that allows the structural and functional examination of the α1-subunit TMD for one of the brain's most prevalent inhibitory-neurotransmitter receptors. Our description of a novel crystal structure for a functional GLIC-GABA A Rα1 chimera has enabled the structural interrogation of the GABA A R α-subunit TMD. This domain contains numerous modulator-binding sites, including the GABA ion channel. We revealed several important facets. Firstly, we obtained a precise structural location for the binding site for the potentiating neurosteroids. The GABA A Rsubunit interface is evidently critical for modulation by potentiating neurosteroids. Previously, we had proposed that two separate sites were necessary to explain the direct activation of the receptor by neurosteroids and the potentiation of receptor function. However, in the new structure presented here, both activation and potentiation apparently proceed from a single interfacial binding site, a feature that is explicable by using a Monod-Wyman-Changeux model of receptor operation 49 . Secondly, whereas potentiating neurosteroids discretely bind between subunits near the lipid interface, we found that inhibitory neurosteroids seemingly bind to a discrete intrasubunit TMD site.
Thirdly, we definitively describe the desensitization gate for GABA A Rs, caused by constriction at the base of the ion channel. This structural feature is conserved across anion-permeable pLGICs captured in desensitized-like states (like the GABA receptor β3 and GlyRα1 bound to ivermectin). It is also notable that in the recent crystal structure of a heteromeric α4β2 nAChR 50 , a constriction of the ion channel is evident at the cytosolic portal, consistent with a nonconductive, desensitized state. This finding, together with the structure presented here, suggests that common structural features underpin desensitization in both anion-and cation-permeable pLGICs.
Finally, it is clear that the α-subunit interface in GABA A Rs also forms a binding site for another important class of modulators, the intravenous general anesthetics (such as etomidate), which can photolabel the β + -α − interface at a methionine (M235) in the α1 subunit 51 (Fig. 7a) . Our crystal structures reveal that the etomidate and neurosteroid-binding sites are nonoverlapping, such that the same interface can accommodate the simultaneous binding of both molecule types (Fig. 7a) . This probably explains why neurosteroids will enhance potentiation by etomidate 52 .
Further interrogation of the chimera structure at the subunitsubunit interface also revealed a lateral aqueous tunnel. This tunnel originates from the lipid bilayer and opens into the ion channel at the 15′ level. This tunnel is part of a larger intersubunit cavity lined by residues implicated in anesthetic binding; it is also partly occupied by CHS (Fig. 7b,c and Supplementary Fig. 6d) .
Given the significant role neurosteroids play in anxiety, stress and other neurological disorders 11 , these modular structures provide a new template for exploring how allosteric sites can be used by drugs to modulate GABA A Rs, an area of considerable physiological, pathological and therapeutic relevance for the brain.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. 
ONLINE METHODS
Construction of chimeric receptor construct.
The murine GABA A Rα1 subunit and GLIC (with an α7 nicotinic acetylcholine receptor (nAChR) signal peptide sequence; gift from P.-J. Corringer, Pasteur Institute) were subcloned into pRK5. Chimeric GLIC-GABA A Rα1 subunits were generated by an overlap PCR protocol as previously described 10 and subcloned into pRK5 for expression in Xenopus oocytes. Single point mutations, which modify the desensitization properties of the receptor, were introduced into M2 and the M1-M2 linker of the chimera using a single PCR reaction. Constructs were subcloned into pFastBac1 for baculovirus generation and insect cell expression. The cDNA coding for the final GLIC-GABA A Rα1 G258V cryst construct consisted of (from N to C terminus): the signal peptide sequence of the α7 nAChR (as previously described for GLIC 53 ), the mature sequence of the chimera in which the single-point mutation G258V was introduced into the M2 α-helix, the large intracellular loop of GABA A Rα1 between M3 and M4 (residues 312-389) replaced by the short GLIC linker, -SQPARAA-, and an octa-histidine tag incorporated at the carboxyl terminus for purification. Truncation of the M3-M4 linker in the chimera did not have any impact on receptor assembly or function. Residue numbering used throughout reflects the respective domain numbering for the two WT subunits (GLIC and GABA A Rα1), whereby residue number 1 is the start of the mature protein (Supplementary Fig. 1 ).
Protein expression and purification. Bacmid DNA and recombinant baculovirus for the GLIC-GABA A Rα1 G258V cryst were generated using standard methods (Bac-to-Bac system, Thermo Scientific). P2 virus was used to infect Sf9 insect cells (Invitrogen, authenticated at source, not tested for mycoplasma) grown at 27 °C in InsectXpress media (Lonza). Post-infection (72 h) cells were collected by centrifugation and cell pellets were either used immediately or flash frozen in liquid nitrogen. All purification steps were performed at 4 °C. Expression of chimera constructs and detergent solubilization were initially assessed in smallscale expression and purification screens (by immobilized metal affinity chromatography; IMAC) and evaluated by means of SDS-PAGE. Suitable constructs were used in scale-up experiments. Cell pellets were resuspended in buffer containing: 20 mM Tris, pH 8, 300 mM NaCl (Buffer A), protease inhibitors (Roche) and 0.5 mM phenylmethylsulfonyl fluoride, before being disrupted by sonication. Following clearing of the lysate, cell membranes were isolated by centrifugation at 125,000g. Membranes were solubilized in Buffer A with 1% n-Dodecyl-β-D-maltopyranoside (DDM, Anatrace) and 0.1% cholesteryl hemisuccinate (CHS, Sigma) for 2 h with gentle stirring. Solubilized membranes were centrifuged at 125,000g to remove insoluble material, and the solubilized chimera recovered by binding to TALON-Co 2+ affinity resin (ClonTech). Resin was recovered and packed into an EconoPac column and washed with Buffer A containing 0.03% DDM, 0.001% CHS and 25 mM imidazole. Bound receptor was eluted using 250 mM imidazole, concentrated and further purified on a size-exclusion column (Superose 6 10/300 GL; GE Healthcare) equilibrated in Buffer A with 0.03% DDM and 0.001% CHS. Fractions corresponding to the pentameric receptor-detergent complex were pooled and concentrated to 2-8 mg/ml for crystallization trials. All representative protein purification data were replicated by at least three independent experiments.
Protein crystallization. Initial crystallization screens revealed a number of conditions under which crystals of GLIC-GABA A Rα1 G258V cryst could form. The best quality diffracting crystals were obtained by vapor diffusion in sitting drops (100 nl protein, 100 nl reservoir solution) at 16 °C. An initial structure (at 3.3-Å resolution) for the proton-bound form was solved from crystals grown in 12-16% PEG 4000, 100 mM NaCl, 100 mM Li 2 SO 4 , and 100 mM sodium acetate, pH 4-4.5. These conditions were used to obtain crystals for co-crystallization studies (with THDOC and PS), as described below. The resolution of the proton-bound form was improved to 2.8 Å by growing crystals in 100 mM NaCl, 100 mM sodium acetate, pH 4.6, and 12% PEG 6000. Crystals for both proton-bound forms belonged to the C2 space group and exhibited near-identical structures.
Co-crystallizing the chimera with THDOC was achieved using dilute receptor-detergent complexes isolated by size exclusion, incubated with THDOC (at 20 µM) and then concentrated to ~6 mg/ml before setting crystallization drops. The best-diffracting (<4 Å) crystals grew in 12-16% PEG 4000, 100 mM NaCl, 100 mM Li 2 SO 4 , and 100 mM sodium acetate, pH 4-4.5.
To obtain the PS-bound structure, receptor-detergent complexes isolated by size exclusion were incubated with neurosteroid at 50 µM and then concentrated to 2 mg/ml before being mixed with precipitant in sitting drops. Crystals obtained by co-crystallization with PS typically exhibited improved diffraction (~3 Å) compared to those incubated with THDOC.
All crystals were cryoprotected by brief soaks in reservoir solution supplemented with 20% glycerol (and DDM at 0.03%) before being flash frozen in liquid nitrogen. For ligand-bound structures, ligands were also included in the cryoprotectant solution (0.1 mM THDOC or 0.2 mM PS). Stock solutions of ligands were first prepared in DMSO and then diluted in size-exclusion buffer.
X-ray diffraction data collection. Diffraction data were collected at the Diamond Light Source (Harwell, UK) on beamlines I02 and I24 and at the European Synchrotron Radiation Facility (Grenoble, France) on beamline ID23-1 and ID23-2. All data sets were collected at a 0.98-Å wavelength. Data indexing, integration and scaling was performed using Xia2 and programs in the CCP4 suite 54, 55 . Diffraction data for determining the THDOC-bound structure was merged from two data sets collected from the same crystal. Data collection statistics are shown in Table 1 . All crystals belonged to the C2 space group.
Crystal structure determination. The structure of the chimera was solved by molecular replacement in Phaser 56 and using the structure of GLIC (PDB 4HFI) as the search probe. An initial model of the receptor was then built using automated model building in Buccaneer 57 , followed by iterative rounds of manual model building in Coot 58 and refinement in BUSTER and then restrained refinement in PHENIX 59 to obtain final models. Noncrystallographic symmetry restraints were used throughout refinement, though this was relaxed for residues that form crystal contacts between subunit extracellular domains. Translation-Libration-Screw parameters (two groups per subunit) and isotropic B factors were also used in refinement in PHENIX. The final model contained one pentameric assembly in the asymmetric unit. Electron density maps were of sufficient quality to enable modeling of the entire receptor backbone, except for the 13 C-terminal residues of the α1 subunit and octa-histidine tag (considered to be disordered). Residue side chains were built except for Met4, Arg58, Arg62, Lys64, Lys170, Glu249, Lys311, Lys390 and Arg393. During refinement, we consistently observed additional electron density at the subunit interface in the TMD at the level of the 'anesthetic pocket' . We assigned this density to CHS, contributed by the purification procedure. The best fit of CHS to the density occurred when the hemisuccinate group protruded into the TMD, forming polar contact with Ser269. Long 'sausage-shaped' regions of electron density lying approximately parallel to TMD helices were assigned to the acyl chain of detergent (DDM) molecules (used throughout the purification steps).
Peaks in electron density in the lower half of the pore were assigned to Cl − and a self-stabilized pentagon of water molecules. We assigned these peaks on the basis of the Cl − -selective nature of the chimera's ion channel, the presence of NaCl throughout receptor purification and crystallization procedures and the spatial overlap with analogous cation sites revealed in high-resolution structures of the cation-selective GLIC receptor 17 . Additional peaks in difference density maps in the ECD of the chimera could be assigned to ions contributed by the crystallization solutions, as previously observed in crystal structures of the WT GLIC receptor.
The model of the proton-bound receptor form was used as a search probe to obtain phases for ligand-bound models and as a reference model restraint during refinement. After initial rounds of refinement, electron density maps for chimeric receptor models enabled the identification of bound ligands. Ligands were placed into the model with restraint files (used in model building and refinement) generated using the Grade Server (http://grade.globalphasing.org/cgi-bin/grade/server. cgi). Structures were refined using PHENIX 59 and stereochemical properties of all models were assessed using MolProbity 60 . For all structures, 96% of residues lie in the favored region of the Ramachandran plot. 0.39% of residues for the proton-bound and PS-bound receptor structures and 0.19% of residues for the THDOC-bound structure lie in the outlier region of the plot. The Molprobity scores are 1.78 (99 th percentile), 1.78 (100 th percentile) and 1.88 (100 th percentile) for the proton-, THDOC-and PS-bound structures, respectively.
Pore dimensions were generated using HOLE 61 , and solvent-accessible pore and tunnel representations were generated using CAVER (ver 3.0, PyMOL plugin). Sequence alignments were generated using PROMALS3D 62 and ClustalW.
Structural alignments and superimposition calculations were generated using PyMOL (http://www.pymol.org/; Molecular Graphics System, version 1.8 Schrödinger, LLC) or the superpose command in CCP4mg 55 . Electrostatic surface potentials were generated using the APBS plug-in from PyMOL. Residue conservation was mapped onto the higher-resolution structure of the protonbound form using ProtSkin 63 and aligned with the THDOC-bound structure for visual representation. Structural figures were made using PyMOL.
Thermal stability of the protein. Detergent-solubilized (DDM or CHS) purified receptors were used in thermostability binding experiments. Samples were aliquoted in PCR tubes and heated over 40-90 °C for 1 h. After a brief centrifugation step to remove precipitates, samples were run on a Superose 6 Increase 3.2/300 column (GE Healthcare) in 20 mM Tris, pH 8, 300 mM NaCl, 0.03% DDM and 0.001% CHS, attached to an HPLC system (Shimadzu) with automated sample loading. The UV absorbance intensity of the pentameric SEC peak was monitored relative to the unheated (4 °C) control sample. The relative intensities were fit with a sigmoidal equation to determine the melting temperature (T m , which equates to that causing a 50% reduction in pentameric peak intensity). To assess whether THDOC was able to thermostabilize the detergent-receptor complex, purified protein was incubated in varying concentrations of THDOC at 62 °C (determined T m ) for 1 h before implementing SEC analysis as described above. It was apparent that 10-100 µM THDOC was sufficient to increase thermal stability.
Molecular dynamics simulations.
The apo protein structure of GLIC-GABA A Rα1 G258V cryst was used for the docking calculations. Missing side chains were added using Modeller 9.16 (ref. 64). PROPKA3.0 (ref. 65 ) was used to evaluate the pK a values of ionizable residues. All histidines were modeled as the Nδ tautomer, and E302, which is adjacent to the proposed PS-binding site, was modeled in protonated form. THDOC and PS were docked into their proposed binding sites using AutoDock Vina 1.1.2 (ref. 66) . For the purpose of conducting molecular dynamics simulations of the protein in complex with the docked poses, the protein was inserted into a 128 Å × 128 Å POPC 67 bilayer using LAMBADA 68 , and a copy of the pose of interest was copied into each of the five binding sites of the homomeric pentamer. All lipids with atoms within 0.8 Å of either the protein or the ligand were then deleted from the membrane. The ligands were parameterized using the gaff2 force field with RESP charges. The ff14SB (ref. 69) and Lipid14 (ref. 70 ) force fields were used for the protein and the lipids, respectively. The system was solvated using a minimum spacing of 15 Å between the protein and the edge of the box in the direction perpendicular to the membrane. NaCl (150 mM) was added and the system was neutralized. This yielded systems containing ~210,000 atoms. The simulations were performed using Amber16. SHAKE 71 was applied to constrain bonds to hydrogen atoms, allowing a time step of 2 fs. A nonbonded cutoff of 10 Å was applied, and long-range electrostatics were included using the particle mesh Ewald 72 method. The temperature was kept at 298 K using Langevin dynamics with a collision frequency of 1 ps −1 . Pressure was kept at 1 atm using the Monte Carlo barostat with semi-isotropic pressure coupling. The production simulations were run for 50 ns. The equilibration protocol consisted of a 5,000-step steepest descent minimization, followed by a 10 ps simulation in which the system was heated from 1 K to 100 K, during which the protein, ligands, and lipid phosphate atoms were restrained using a force constant of 2 kcal/mol/Å 2 . Next, a 100-ps simulation was used to further heat the system to 298 K while applying a pressure of 1 atm, during which only the lipid phosphate atoms were restrained.
DNA cloning and mutagenesis. cDNA constructs for the GLIC-GABA A Rα1 chimera and all associated point mutations in this study were cloned into the pRK5 vector. Site-directed mutagenesis was performed using standard inverse PCR methods. Successful mutagenesis was confirmed by sequencing over the relevant sites (Source Bioscience).
Electrophysiological characterization. X. laevis oocytes were removed using schedule I procedures as defined under the UK Home Office guidelines (Animals (Scientific procedures) Act, 1986). Oocytes were injected with cDNA (at 10-30 ng/µl) encoding for the GLIC-GABA A Rα1 chimera, mutants and GABA A Rs and incubated in Barth's solution containing: 88 mM NaCl, 1 mM KCl, 0.33 mM Ca(NO 3 ) 2 , 0.41 mM CaCl 2 , 0.82 mM MgSO 4 , 2.4 mM NaHCO 3 , 10 mM HEPES, pH adjusted to 7.6 with NaOH.
Oocytes expressing receptors were used from 1-4 d post injection and were superfused with a solution for proton-gated receptors containing 100 mM NaCl, 2 mM KCl, 2 mM CaCl 2 , 1 mM MgCl 2 , 10 mM MES, and 0.01 mM EDTA, pH adjusted with 1M NaOH and a solution for GABA-gated receptors containing 100 mM NaCl, 2 mM KCl, 2 mM CaCl 2 , 1 mM MgCl 2 , 5 mM HEPES, pH adjusted to 7.4 with NaOH (Ringer solution). Membrane currents were recorded using two-electrode voltage clamp with 1-3 MΩ electrodes filled with 3 M KCl. An Axoclamp 2B amplifier, a Digidata 1322A interface and pClamp 8 (Molecular Devices) were used to record membrane currents for analysis. Currents were digitized at 500 Hz and filtered at 50 Hz. Oocytes were voltage-clamped (V h ) at −60 mV, and experiments were conducted at room temperature. Desensitizing and steady-state currents were induced by proton applications up to 1 min. The extent of desensitization was determined as (1 − I residual /I peak ), where I peak is the peak current and I residual is the residual current remaining at the end of the agonist application. All modulators were co-perfused with the appropriate agonist at the concentrations described in the text, following dilutions of at least 1,000-fold from stock concentrations in either distilled water or DMSO. The effects of PS were additionally assessed for various receptor constructs after 1 min of preincubation followed by co-incubation.
Current-voltage plots were derived initially in normal Ringer solution (high external Cl − , 108 mM) and subsequently in low external Cl − Ringer (27 mM), following sodium isethionate equimolar substitution for NaCl. Between drug applications, membrane voltage was maintained at −60 mV before transiently being stepped (by 20-mV jumps) up to +20 mV before the application of protons (pH 5.5 saline, see above) to activate the chimera.
After normalization of the data, concentration-response curves for protons and modulation by THDOC, or direct effects of THDOC, were fitted by the Hill equation: where y max represents the noninhibited current and y min the pedestal of the inhibited current.
All representative electrophysiological membrane current data were replicated by at least three independent experiments. Assuming PS behaves as a noncompetitive antagonist, proton currents were inhibited according to the following state function, which was used to generate theoretical PS concentration inhibition curves (Supplementary Fig. 8g The curves were fit using empirical values to reproduce the experimental data shown in Figure 6e , and the weighting factor (I min + (1 − I min )) was used to provide a plateau in the inhibition curve. The value of D2 increased 3-4-fold by PS and E was similarly increased to E2, by approximately 3-fold. K b remained largely unaffected (1-2-fold changes).
A Life Sciences Reporting Summary for this article is available.
Data availability. Atomic coordinates and structure factors have been deposited in the Protein Data Bank (PDB) under accession codes PDB 5OSA, PDB 5OSB and PDB 5OSC for the GLIC-GABA A Rα1 chimera alone, with bound THDOC and with pregnenolone sulfate, respectively. Source data for Figures 1d, 5c ,g and 6d,e are available with the paper online.
